Welcome to Cannabinoid Clinic, an education project powered by Higher Learning LV. This series provides cannabis and hemp industry professionals with easily digested cannabinoid profiles that ask little of your time—but provide plenty of science-based information.
There are two categories of cannabinoids: Phytocannabinoids and endocannabinoids. Phytocannabinoids are those produced by cannabis/marijuana/hemp, while endocannabinoids are made by the human body. This series covers both.
Cannabigerol (CBG) is the result of CBGA, the acidic precursor for this pivotal cannabinoid. It is considered a minor cannabinoid because it is typically available in relatively low volumes compared to major cannabinoids such as cannabidiol (CBD) and tetrahydrocannabiol (THC) (under one percent).
Although not psychoactive, anecdotal testimonies and scientific research has revealed that CBG may help patients suffering from a range of conditions, including glaucoma, cancer, and Huntington's disease.
First isolated in 1964 by Dr. Yehiel Gaoni and Dr. Raphael Mechoulam in Israel, CBG offers anti-inflammatory and antibacterial powers that may be of value in the treatment of a wide range of disease states and conditions.
Like many cannabinoids, the primary potential medicinal benefits of CBG are numerous and include benefits for patients with glaucoma, cancer, Huntington's disease, inflammatory bowel disease, and staph infections resulting from bacteria.
A 2013 study involving mouse subjects entitled "Beneficial Effects of the Non-psychotropic Plant Cannabinoid Cannabigerol on Experimental Inflammatory Bowel Disease" revealed that CBG may be helpful in the treatment of inflammatory bowel disease (IBD) due to its anti-inflammatory effects. The authors of this study recommended additional experimentation of CBG in clinical trials involving humans.
A 2014 study involving rats entitled "Cannabinoid Effects on Experimental Colorectal Cancer Models Reduce Aberrant Crypt Foci (ACF) and Tumor Volume: A Systematic Review" showed that CBG may fight cancer via a mechanism involving the blockage of receptors that cause cancer cell growth. CBG was also found to prevent the growth of colorectal cancer cells.
A 2020 study entitled "Uncovering the Hidden Antibiotic Potential of Cannabis" explored the antibacterial properties of CBG. It found that the cannabinoid may offer considerable antibacterial abilities, particularly for methicillin-resistant strains of Staphylococcus aureus (MRSA) that result in staph infections.
by: Curt Robbins
LeafWize Naturals CBD, CBG, CBN and Delta8
10% Off Everything at leafwize.com w/ Code: CJ10
